A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
A phase 3 trial of Amivantamab, Cetuximab, Bevacizumab and Leucovorin (folinic acid) in colorectal cancer, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy is a phase 3 interventional study registered as NCT06750094 by Janssen Research & Development, LLC, with 700 participants planned, started 2024-12-12 and due to reach its primary completion in 2027-12-15. Interventions recorded: Amivantamab, Cetuximab, Bevacizumab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin and Irinotecan.
Similar pages
not linked directly; found by shared links- TrialA Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Shares Leucovorin (folinic acid), Amivantamab, Cetuximab, Johnson & Johnson and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Shares Cetuximab, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialA Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Shares Cetuximab, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Shares Amivantamab, Johnson & Johnson and the tag pipeline.
- TrialA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Shares Amivantamab, Johnson & Johnson and the tag pipeline.
- TrialA Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson and the tag pipeline.
- TrialA Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Shares Amivantamab, Johnson & Johnson and the tag pipeline.
- TrialA Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson and the tag pipeline.